Impact of Femoral Vascular Closure Devices and Antithrombotic Therapy on Access Site Bleeding in Acute Coronary Syndromes | Zendy

Timothy A. Sanborn | Zendy; Ramin Ebrahimi | Zendy; Steven V. Manoukian | Zendy; Brent McLaurin | Zendy; David A. Cox | Zendy; Frederick Feit | Zendy; Martial Hamon | Zendy; Roxana Mehran | Zendy; Gregg W. Stone | Zendy

Open Access

Impact of Femoral Vascular Closure Devices and Antithrombotic Therapy on Access Site Bleeding in Acute Coronary Syndromes

Author(s) -

Timothy A. Sanborn,

Ramin Ebrahimi,

Steven V. Manoukian,

Brent McLaurin,

David A. Cox,

Frederick Feit,

Martial Hamon,

Roxana Mehran,

Gregg W. Stone

Publication year - 2010

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.109.896704

Subject(s) - bivalirudin , medicine , vascular closure device , percutaneous coronary intervention , antithrombotic , acute coronary syndrome , odds ratio , hematoma , surgery , femoral artery , cardiology , myocardial infarction

The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial demonstrated that bivalirudin monotherapy significantly reduces major bleeding compared with heparin (unfractionated or enoxaparin) or bivalirudin plus a glycoprotein IIb/IIIa inhibitor in acute coronary syndromes. Whether vascular closure devices (VCD) impact these results is unknown. Therefore, this study sought to determine whether VCD impact major access site bleeding (ASB) in patients with acute coronary syndromes undergoing early invasive management by the femoral approach.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research